Home » Speaker





As an Associate Professor and Director of the Retina Service from the Department of Ophthalmology, University of Montreal, I lead the clinical/surgical side of our translational research team. My main focus is on surgical management of complicated vitreoretinal diseases, academic teaching, and on surgical translational research. As a vitreoretinal surgeon at the Department of Ophthalmology, Maisonneuve-Rosemont Hospital, I have been developing and improving complex vitreoretinal surgical techniques to manage different vitreoretinal diseases, including vitreoretinal endoscopy (Rezende et al. 2015, suprachoroidal buckling (El Rayes et al. 2016, submitted), and transconjunctival drainage of choroidal detachment (Rezende et al. 2012). On the academic teaching side, I have been in charge of the Vitreoretinal Fellowship Program from the Retina Service, Department of Ophthalmology, University of Montreal for the past 4 years. I am also in charge of an Ophthalmology residents Exchange Program between University of Montreal and University of São Paulo and Pontifícia Universidade Católica, Rio de Janeiro, Brazil. I also lead the surgical simulation virtual reality teaching unit at the Department of Ophthalmology, University of Montreal. In Brazil, I still serve as an Associate Professor at the Department of Ophthalmology, Pontifícia Universidade Católica, Rio de Janeiro. As a surgical translational researcher, I have developed surgical techniques to obtain vitreous biopsies in an ambulatory setting (Rezende et al. 2014), providing instrumental material for our Neuro-Vascular Biology Research Unit. Our main focus is on discovering new pathways and molecules to explain and treat chorio-retinal vascular diseases of the eye, including diabetic retinopathy and age-related macular degeneration, among others. Our work on Omega-3 metabolites has shown its encouraging effects on anti-angiogenesis experimentally (Sapieha et al. 2011) and clinically (Rezende et al. 2014). In the past five years, we have been discovering molecular guidance cues for abnormal neovascular tissue growth in the presence of retinal ischemia. We have published recent work demonstrating clinical evidence of involvement of the guidance cue Semaphorin 3A in diabetic macular edema and in proliferative diabetic retinopathy (Cerani et al. 2013; Dejda et al. 2014). In collaboration with Harvard Medical School, we are advancing our knowledge in different forms of neovascular age-related macular degeneration (Joyal et al. 2016).